Physician profile
Taylor Proctor
NPI 1003510223
$1,988.46
in general payments reported to CMS, 2019-2025
25 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $290 · 2024: $566 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.47 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $317.86 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $234.26 | 2024-2025 | Tremfya |
| Abbvie INC. | $200.44 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $188.41 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $137.34 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $119.92 | 2023-2025 | |
| Genzyme Corporation | $89.80 | 2023-2025 | |
| Amgen INC. | $88.88 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $74.58 | 2025 | Aklief, Nemluvio |
| Incyte Corporation | $66.47 | 2025 | Opzelura |
| Organon LLC | $60.73 | 2025 | Vtama |
| Almirall LLC | $52.12 | 2024-2025 | Seysara |
| E.R. Squibb & Sons, L.L.C. | $50.16 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $48.89 | 2024-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.89 | 2023-2025 | Spevigo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.15 | 2024 | Jublia, Arazlo |
| Ucb, INC. | $28.84 | 2025 | Bimzelx |
| Botanix Sb INC | $20.71 | 2025 | Sofdra |
| Mallinckrodt Hospital Products INC. | $20.25 | 2025 | Acthar |
| Biofrontera INC. | $19.99 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Fresenius Kabi USA, LLC | $18.50 | 2023 | |
| Arcutis Biotherapeutics, INC. | $17.83 | 2025 | Zoryve |
| Lnhc, INC | $17.68 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $15.66 | 2024 | Ycanth |
| Pfizer INC. | $14.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.